Sideris Pharmaceuticals Receives $32,000,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
    Sideris Pharmaceuticals
  • Mailing Address
    200 Clarendon Street 54th Floor Boston, MA 02116
  • Company Description
    Sideris Pharmaceuticals is an independent biopharmaceutical company focused on the development of treatments for diseases of iron overload, including conditions involving maintenance transfusion therapy. Sideris’ lead clinical candidate, SP-420, has the potential to be the best-in-class therapeutic approach as an oral iron chelator.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    MPM Capital
  • Venture Investor
    Hatteras Venture Partners
  • Venture Investor
    Osage Partners
  • Venture Investor
    Novartis BioVenture Fund

Trending on Xconomy